NGL Fine-Chem Limited (NGLFINE.NS) NSE
Currency In INR
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In INR
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
682
First IPO Date
July 08, 2022
| Name | Title | Pay | Year Born |
| Rahul Jayant Nachane | Chief Executive Officer, MD, Chief Ethics Counsellor & Executive Director | 18.35M | 1964 |
| Rajesh Narayan Lawande | Whole Time Director & Chief Financial Officer | 18.21M | 1976 |
| Ahaan Nachane | Vice President | 0 | N/A |
| Shivam Gharat | Company Secretary & Compliance Officer | 0 | N/A |
Headquartered in Mumbai, India, and established in 1981, NGL Fine-Chem Limited operates as a worldwide producer and distributor of pharmaceutical ingredients and intermediates for both veterinary and human health sectors. The company's comprehensive portfolio of active pharmaceutical ingredients (APIs) for animal applications features substances like diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin. For human therapeutic use, they supply APIs including nitazoxanide, atovaquone, and ranolazine. Furthermore, NGL Fine-Chem manufactures various intermediate compounds and offers completed pharmaceutical formulations in both granule and tablet formats.